Joseph L Kim
Overview
Explore the profile of Joseph L Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kim Y, Saenz A
Cureus
. 2024 Dec;
16(12):e75475.
PMID: 39664290
Autoimmune encephalitis is a disorder characterized by an autoantibody-mediated process that leads to brain inflammation. It is associated with neurological symptoms including cognitive issues, psychiatric problems, seizures, and autonomic dysfunctions....
2.
Scheuplein F, Renner F, Campbell J, Campbell R, De Savi C, Eckmann J, et al.
Front Immunol
. 2024 Nov;
15:1411395.
PMID: 39502695
Introduction: The serine/threonine kinase 17B (STK17B) is involved in setting the threshold for T cell activation and its absence sensitizes T cells to suboptimal stimuli. Consequently, STK17B represents an attractive...
3.
Davis A, Brooijmans N, Brubaker J, Stevison F, LaBranche T, Albayya F, et al.
Sci Transl Med
. 2024 May;
16(749):eabp8334.
PMID: 38809966
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease driven by gain-of-function variants in activin receptor-like kinase 2 (ALK2), the most common variant being ALK2. In FOP, ALK2 variants display...
4.
Hatlen M, Schmidt-Kittler O, Sherwin C, Rozsahegyi E, Rubin N, Sheets M, et al.
Cancer Discov
. 2019 Oct;
9(12):1686-1695.
PMID: 31575540
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of...
5.
Gardino A, Evans E, Kim J, Brooijmans N, Hodous B, Wolf B, et al.
Mol Cell Oncol
. 2018 Sep;
5(3):e1435183.
PMID: 30250891
Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in a variety of activation mechanisms. The challenge has been to match these insights...
6.
Subbiah V, Gainor J, Rahal R, Brubaker J, Kim J, Maynard M, et al.
Cancer Discov
. 2018 Apr;
8(7):836-849.
PMID: 29657135
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer....
7.
Evans E, Gardino A, Kim J, Hodous B, Shutes A, Davis A, et al.
Sci Transl Med
. 2017 Nov;
9(414).
PMID: 29093181
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that...
8.
Liu L, Lee M, Kim J, Whittington D, Bregman H, Hua Z, et al.
Bioorg Med Chem
. 2016 May;
24(13):3093.
PMID: 27234892
No abstract available.
9.
Liu L, Lee M, Kim J, Whittington D, Bregman H, Hua Z, et al.
Bioorg Med Chem
. 2016 Apr;
24(10):2215-34.
PMID: 27085672
One of the challenges for targeting B-Raf(V600E) with small molecule inhibitors had been achieving adequate selectivity over the wild-type protein B-Raf(WT), as inhibition of the latter has been associated with...
10.
Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, et al.
Cancer Discov
. 2015 Mar;
5(4):424-37.
PMID: 25776529
Unlabelled: Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has...